What Is MOTS-c and How Does It Work
MOTS-c is a 16-amino-acid peptide encoded not in nuclear DNA but in the mitochondrial genome, within the 12S rRNA region of the MT-RNR1 gene. It belongs to a small family of "mitochondrial-derived peptides" (MDPs) discovered over the past decade, which act as signaling molecules produced directly by mitochondria rather than the cell's main genome. Under metabolic stress, MOTS-c is proposed to translocate to the nucleus and regulate stress-response gene expression, and it has been studied for a downstream role in activating AMPK - a central cellular energy-sensing pathway - primarily in skeletal muscle tissue.
Because skeletal muscle accounts for the large majority of insulin-stimulated glucose disposal in the body, researchers have proposed that muscle-targeted AMPK activation is the mechanistic basis for MOTS-c's studied effects on glucose uptake, fatty-acid oxidation, and insulin sensitivity. Circulating MOTS-c levels have also been reported to decline with age in some human studies, which is part of why it is discussed in the research literature as a candidate "mitochondrial peptide of aging" - though that framing is still an active area of investigation, not an established clinical fact.
Research Dosing
This is an important caveat for MOTS-c specifically: there is no completed, peer-reviewed human dose-ranging trial establishing an optimal or validated dose. Everything below reflects informal research-community convention, not clinical evidence.
| Context | Dose (commonly cited) | Frequency | Route |
|---|---|---|---|
| Research-community convention | ~5–10mg per dose | 2–3× weekly (some protocols use lower daily doses) | SubQ injection |
| Validated human clinical dose | Not established | Phase 2a human trial ongoing as of 2026 | — |
Context: The 5–10mg / 2–3×-weekly range circulating in research-community protocol guides is not derived from a completed, published human dose-finding study. Treat any specific figure you see for MOTS-c as an informal convention, not a validated clinical dose, until controlled trial data is published.
Regulatory Status
MOTS-c is not an FDA-approved drug for any indication. Products sold as "MOTS-c" are marketed as research chemicals for laboratory research use only, not for human consumption. As of mid-2026, industry and trade coverage indicated that the FDA's Pharmacy Compounding Advisory Committee (PCAC) had reviewed MOTS-c, in both free-base and acetate forms, for potential inclusion on the FDA's 503A bulk drug substances list. That review process - even if the outcome is favorable - determines eligibility for compounding under specific conditions; it is not the same as FDA approval of MOTS-c as a drug, and as of this writing MOTS-c has not been approved for any medical use. Consult a qualified healthcare provider before considering any peptide protocol.
What Research Shows
The seminal efficacy data on MOTS-c comes from a 2015 mouse study, which found that MOTS-c injections activated AMPK in skeletal muscle, improved whole-body insulin sensitivity, and prevented both age-related and diet-induced insulin resistance and obesity in mice. That mechanistic and efficacy picture has since been extended by additional rodent and cell-based studies looking at its effects on plasma metabolites and metabolic pathways. It is important to be direct about what this evidence does and does not show: the efficacy data supporting MOTS-c's metabolic effects is, as of this writing, predominantly preclinical (rodent and in-vitro). A randomized, placebo-controlled Phase 2a trial evaluating 12 weeks of MOTS-c in adults with prediabetes and overweight/obesity was underway in 2026, but had not published results at the time of writing - so direct human efficacy evidence for insulin sensitivity remains an open question rather than an established finding.